Gain Therapeutics (NASDAQ:GANX) Posts Earnings Results, Beats Estimates By $0.07 EPS

Gain Therapeutics (NASDAQ:GANX) issued its earnings results on Thursday. The company reported ($0.11) earnings per share for the quarter, beating the consensus estimate of ($0.18) by $0.07, Zacks reports.

Gain Therapeutics Price Performance

Shares of NASDAQ:GANX traded down $0.06 during midday trading on Friday, reaching $2.01. The company’s stock had a trading volume of 81,304 shares, compared to its average volume of 279,685. The business’s fifty day simple moving average is $2.23 and its 200-day simple moving average is $2.05. The company has a debt-to-equity ratio of 0.04, a current ratio of 2.99 and a quick ratio of 2.99. Gain Therapeutics has a fifty-two week low of $0.89 and a fifty-two week high of $4.04. The company has a market capitalization of $53.32 million, a P/E ratio of -1.83 and a beta of 0.14.

Analysts Set New Price Targets

A number of research analysts have commented on the stock. Scotiabank began coverage on shares of Gain Therapeutics in a research note on Friday, March 7th. They set a “sector outperform” rating and a $12.00 price target for the company. Chardan Capital restated a “buy” rating and set a $6.00 target price on shares of Gain Therapeutics in a research report on Friday. HC Wainwright reiterated a “buy” rating and issued a $8.00 price target on shares of Gain Therapeutics in a research report on Monday, March 17th. Roth Mkm reissued a “buy” rating and set a $7.00 price objective on shares of Gain Therapeutics in a report on Tuesday, December 24th. Finally, Roth Capital upgraded shares of Gain Therapeutics to a “strong-buy” rating in a research note on Thursday, December 5th. Five equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $8.20.

Gain Therapeutics Company Profile

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.